Mario Alberto Occhipinti (Mario Occhipinti)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Venues

Tumori

Cancer immunology, immunotherapy : CII

Journal of personalized medicine

Drug safety - case reports

This page only lists publications with an associated author ORCID identifier.

Publications

Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Alberto Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. Tumori (2024)
Rita Leporati, Daniela Miliziano, Teresa Beninato, Laura Mazzeo, Sara Manglaviti, Marta Brambilla, Mario Alberto Occhipinti, Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. Tumori (2024)
Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Alberto Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. Tumori 110 (3) (2024)
Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Alberto Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. Tumori 110 (3) (2024)
Caterina Zanella, Alberto Giovanni Leone, Luca Zambelli, Achille Bottiglieri, Luca Canziani, Marta Brambilla, Giuseppe Lo Russo, Marco Platania, Filippo De Braud, Mario Alberto Occhipinti
Paraneoplastic neurological syndromes in patients affected by SCLC: a case series. Tumori 108 (6) (2022)
Andrea Spagnoletti, Marco Platania, Marta Brambilla, Mario Alberto Occhipinti, Luca Canziani, Antonello Cabras, Leonardo Provenzano, Alberto Giovanni Leone, Paolo Ambrosini, Arsela Prelaj
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. Tumori 108 (6) (2022)
Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto, Francesca Rastelli, Alain Gelibter, Rita Chiari, Olga Nigro, Michele De Tursi, Sergio Bracarda, Stefania Gori, Francesco Grossi, Melissa Bersanelli, Lorenzo Calvetti, Vincenzo Di Noia, Mario Scartozzi, Massimo Di Maio, Paolo Bossi, Alfredo Falcone, Fabrizio Citarella, Francesco Pantano, Corrado Ficorella, Marco Filetti, Vincenzo Adamo, Enzo Veltri, Federica Pergolesi, Mario Alberto Occhipinti, Linda Nicolardi, Alessandro Tuzi, Pietro Di Marino, Serena Macrini, Alessandro Inno, Michele Ghidini, Sebastiano Buti, Giuseppe Aprile, Eleonora Lai, Marco Audisio, Salvatore Intagliata, Riccardo Marconcini, Davide Brocco, Giampiero Porzio, Marta Piras, Erika Rijavec, Francesca Simionato, Clara Natoli, Marcello Tiseo, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer immunology, immunotherapy : CII (2021)
Mario Alberto Occhipinti, Marta Brambilla, Giulia Galli, Sara Manglaviti, Maristella Giammaruco, Arsela Prelaj, Roberto Ferrara, Alessandro De Toma, Claudia Proto, Teresa Beninato, Emma Zattarin, Giuseppe Lo Russo, Alain Jonathan Gelibter, Maurizio Simmaco, Robert Preissner, Marina Chiara Garassino, Filippo De Braud, Paolo Marchetti
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of personalized medicine 11 (5) (2021)
Marta Brambilla, Giuseppe Lo Russo, Roberto Ferrara, Sara Manglaviti, Marina Chiara Garassino, Mario Alberto Occhipinti
Is hyperprogressive disease a specific phenomenom of immunotherapy? Exploration of targeted anti-tumor therapy 1 (6) (2020)
Alain Gelibter, Mario Alberto Occhipinti, Simona Pisegna, Alessio Cortellini, Enrico Cortesi, Paolo Marchetti
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Lung cancer management 9 (2) (2020)
Mario Alberto Occhipinti, Rosa Falcone, Concetta Elisa Onesti, Paolo Marchetti
Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. Drug safety - case reports 5 (1) (2018)

Mario Alberto Occhipinti.css-eqlu8i{font-size:small;padding-left:4px;} (Mario Occhipinti)

Publication Activity (10 Years)

Top Topics

Top Venues

Mario Alberto Occhipinti (Mario Occhipinti)